NO980095L - New quinoxaline and quinoxalinyl alkane phonic acids - Google Patents
New quinoxaline and quinoxalinyl alkane phonic acidsInfo
- Publication number
- NO980095L NO980095L NO980095A NO980095A NO980095L NO 980095 L NO980095 L NO 980095L NO 980095 A NO980095 A NO 980095A NO 980095 A NO980095 A NO 980095A NO 980095 L NO980095 L NO 980095L
- Authority
- NO
- Norway
- Prior art keywords
- free
- quinoxalinyl
- esterified
- alkane
- aliphatic
- Prior art date
Links
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title abstract 4
- -1 quinoxalinyl alkane Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Quinoksalin- og quinoksalinylalkan-fosfonsyrer med formel I (I). der R, er fri eller forestret karboksy eller fri eller delvis forestret fosfon, R2 og R3 er hver uavhengig av hverandre hydrogen eller et alifatisk radikal, radikalene R,, R5 og R^ er hver uavhengig av hverandre hydrogen, et alifatisk hydrokarbonradikal, fri eller foretret hydroksy, fri eller foretret merkapto eller oksydert fri eller foretret merkapto, usubstitu- ert eller alifatisk substituert amin, nitro, fri eller forestret eller amidert karboksy, cyano, fri eller amidert sulfamoyl, halogen eller trifluormetyl og X er et toverdig alifatisk radi- kal, og deres tautomerer og/eller salter har NMDA-antagonistiske egenskaper og kan bli anvendt i behandling av patologiske tilstander som er responsive for blokkering av NMDA-sensitive reseptorer.Quinoxaline and quinoxalinyl alkane phosphonic acids of formula I (I). wherein R 1 is free or esterified carboxy or free or partially esterified phosphon, R 2 and R 3 are each independently hydrogen or an aliphatic radical, the radicals R 1, R 5 and R 2 are each independently hydrogen, an aliphatic hydrocarbon radical, free or preferred hydroxy, free or preferred mercapto or oxidized free or preferred mercapto, unsubstituted or aliphatic substituted amine, nitro, free or esterified or amidated carboxy, cyano, free or amidated sulfamoyl, halogen or trifluoromethyl and X is a dihydric aliphatic radical , and their tautomers and / or salts have NMDA antagonistic properties and can be used in the treatment of pathological conditions responsive to blocking NMDA-sensitive receptors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH200995 | 1995-07-10 | ||
| PCT/EP1996/002866 WO1997003079A1 (en) | 1995-07-10 | 1996-07-01 | Novel quinoxaline- and quinoxalinylalkane-phosphonic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO980095D0 NO980095D0 (en) | 1998-01-09 |
| NO980095L true NO980095L (en) | 1998-03-05 |
Family
ID=4223780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO980095A NO980095L (en) | 1995-07-10 | 1998-01-09 | New quinoxaline and quinoxalinyl alkane phonic acids |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0837864A1 (en) |
| JP (1) | JPH11508902A (en) |
| KR (1) | KR19990028839A (en) |
| AU (1) | AU6516296A (en) |
| BR (1) | BR9609644A (en) |
| CA (1) | CA2224718A1 (en) |
| CZ (1) | CZ5398A3 (en) |
| HU (1) | HUP9901345A3 (en) |
| IL (1) | IL122872A0 (en) |
| NO (1) | NO980095L (en) |
| PL (1) | PL324340A1 (en) |
| SK (1) | SK2798A3 (en) |
| TR (1) | TR199800022T1 (en) |
| WO (1) | WO1997003079A1 (en) |
| ZA (1) | ZA965800B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ141399A3 (en) * | 1996-10-24 | 1999-07-14 | Novartis Ag | Substituted aminoalkanephosphonic acids, process of their preparation and pharmaceutical compositions containing thereof |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118675A (en) * | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
| IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
-
1996
- 1996-07-01 KR KR1019980700140A patent/KR19990028839A/en not_active Withdrawn
- 1996-07-01 CZ CZ9853A patent/CZ5398A3/en unknown
- 1996-07-01 PL PL96324340A patent/PL324340A1/en unknown
- 1996-07-01 EP EP96924829A patent/EP0837864A1/en not_active Withdrawn
- 1996-07-01 HU HU9901345A patent/HUP9901345A3/en unknown
- 1996-07-01 AU AU65162/96A patent/AU6516296A/en not_active Abandoned
- 1996-07-01 BR BR9609644A patent/BR9609644A/en not_active Application Discontinuation
- 1996-07-01 CA CA002224718A patent/CA2224718A1/en not_active Abandoned
- 1996-07-01 WO PCT/EP1996/002866 patent/WO1997003079A1/en not_active Ceased
- 1996-07-01 JP JP9505465A patent/JPH11508902A/en active Pending
- 1996-07-01 TR TR1998/00022T patent/TR199800022T1/en unknown
- 1996-07-01 SK SK27-98A patent/SK2798A3/en unknown
- 1996-07-01 IL IL12287296A patent/IL122872A0/en unknown
- 1996-07-09 ZA ZA965800A patent/ZA965800B/en unknown
-
1998
- 1998-01-09 NO NO980095A patent/NO980095L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6516296A (en) | 1997-02-10 |
| IL122872A0 (en) | 1998-08-16 |
| CA2224718A1 (en) | 1997-01-30 |
| PL324340A1 (en) | 1998-05-25 |
| CZ5398A3 (en) | 1998-06-17 |
| MX9800332A (en) | 1998-07-31 |
| SK2798A3 (en) | 1998-07-08 |
| HUP9901345A2 (en) | 1999-08-30 |
| HUP9901345A3 (en) | 2000-01-28 |
| NO980095D0 (en) | 1998-01-09 |
| WO1997003079A1 (en) | 1997-01-30 |
| EP0837864A1 (en) | 1998-04-29 |
| JPH11508902A (en) | 1999-08-03 |
| TR199800022T1 (en) | 1998-05-21 |
| KR19990028839A (en) | 1999-04-15 |
| BR9609644A (en) | 1999-05-11 |
| ZA965800B (en) | 1997-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID21927A (en) | AMINOALKANAFOSFONAT ACID IS SUBSTITUTED | |
| MY103021A (en) | Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion inhibitors | |
| ATE233256T1 (en) | 2-PYRIMIDINAMIN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF | |
| KR870000289A (en) | Method for preparing (meth) -acrylic acid derivatives of tricyclodecane | |
| DK0526488T3 (en) | Benzylphosphonsyre-tyrosine kinase inhibitors | |
| DK0863875T3 (en) | New 4- (oxyalkoxyphenyl) -3-oxy-piperines for the treatment of heart and kidney disorders | |
| DE59603876D1 (en) | METHOD FOR PRODUCING CHINAZOLINE DERIVATIVES | |
| ES2122916A1 (en) | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | |
| ATE106863T1 (en) | N-PHENYLBENZAMIDE DERIVATIVES WITH ANTIULCERATIVE AND ANTIALLERGIC ACTIVITY AND PROCESS FOR THEIR PRODUCTION. | |
| ES546935A0 (en) | PROCEDURE FOR THE PREPARATION OF ANILINIC DERIVATIVES FOR THE DETECTION OF REDOX SYSTEMS | |
| BR0005005A (en) | Polymer additive for alkaline zinc or zinc alloy electroplating bath media, alkaline zinc or zinc alloy bath media, process for electroplating zinc and / or zinc alloys on a conductive substrate, and use of the polymer | |
| AU4009585A (en) | Nitrification-inhibiting 1-hydroxypyrazole | |
| HUP9900004A2 (en) | Composition for oxidation dyeing keratin fibres, containing 2-amino 3-hydroxy pyridine and an oxidation base, and dyeing method | |
| ATE60061T1 (en) | CONDENSED SEVEN-MEMBERED RING COMPOUNDS, THEIR PRODUCTION AND USE. | |
| MY132839A (en) | Cycloalkylalkanecarboxamides and the production and use thereof | |
| NO980095L (en) | New quinoxaline and quinoxalinyl alkane phonic acids | |
| DE69008542D1 (en) | CHINOLINE DERIVATIVES, THEIR PRODUCTION AND USE. | |
| ES8604922A1 (en) | PROCEDURE FOR THE PREPARATION OF N-PIRIDYLINDOLS | |
| NO971142L (en) | Bis- (2-haloethyl) aminophenyl-substituted distamycin derivatives as antitumor and antiviral agents | |
| ES8800122A1 (en) | Indene and naphthalene derivatives. | |
| NO972921L (en) | Preparation of cefotaxime and new sodium salts | |
| DK227085D0 (en) | 1-HALOGEN-1-AZOLYL-2,2-DIARYL-ETHANE DERIVATIVES, SALTS AND METAL COMPLEXES THEREOF, AND THEIR PREPARATION AND USE | |
| ES8403456A1 (en) | Antiatherosclerotic | |
| KR930702269A (en) | Phospholipase A2 inhibitor | |
| DK0668852T3 (en) | Substituted orthoethenylphenylacetic acid derivatives |